Yanking ADHD drug angers clinicians[ ... Read the full article ... ]
Health Canada's interpretation of safety data behind its abrupt decision to halt the sale of Adderall is being questioned
By ANDRÉ PICARD
Friday, February 11, 2005 Updated at 7:50 AM EST
The Globe and Mail
Health Canada has stripped a pharmaceutical company of the right to sell a popular drug used for the treatment of hyperactive children in Canada after talks about withdrawing the medication voluntarily broke down.
The highly unusual move -- market authorization has not been withdrawn from any of the 5,000 prescription drugs on the Canadian market since 1999 -- came after Shire Biochem Inc. revealed that at least 20 people taking Adderall XR had died suddenly, and 12 others suffered debilitating strokes. All the deaths and strokes were in the United States. Most involved children who died of stroke, which occurs when a blood vessel to the brain is blocked by a blood clot or bursts, cutting off oxygen to the brain.
Click here for the English text of the Health Canada Advisory. (Also available in French.)
Click here for Shire Biochem press release about the Health Canada decision.